Literature DB >> 10591653

Mouse tumor model for neurofibromatosis type 1.

K S Vogel1, L J Klesse, S Velasco-Miguel, K Meyers, E J Rushing, L F Parada.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by increased incidence of benign and malignant tumors of neural crest origin. Mutations that activate the protooncogene ras, such as loss of Nf1, cooperate with inactivating mutations at the p53 tumor suppressor gene during malignant transformation. One hundred percent of mice harboring null Nf1 and p53 alleles in cis synergize to develop soft tissue sarcomas between 3 and 7 months of age. These sarcomas exhibit loss of heterozygosity at both gene loci and express phenotypic traits characteristic of neural crest derivatives and human NF1 malignancies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591653      PMCID: PMC3079436          DOI: 10.1126/science.286.5447.2176

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  40 in total

1.  Isolation of a stem cell for neurons and glia from the mammalian neural crest.

Authors:  D L Stemple; D J Anderson
Journal:  Cell       Date:  1992-12-11       Impact factor: 41.582

2.  The neurofibromatosis type 1 gene encodes a protein related to GAP.

Authors:  G F Xu; P O'Connell; D Viskochil; R Cawthon; M Robertson; M Culver; D Dunn; J Stevens; R Gesteland; R White
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

Review 3.  Tumor suppressor genes.

Authors:  P W Hinds; R A Weinberg
Journal:  Curr Opin Genet Dev       Date:  1994-02       Impact factor: 5.578

4.  Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis.

Authors:  A G Menon; K M Anderson; V M Riccardi; R Y Chung; J M Whaley; D W Yandell; G E Farmer; R N Freiman; J K Lee; F P Li
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis.

Authors:  E Legius; D A Marchuk; F S Collins; T W Glover
Journal:  Nat Genet       Date:  1993-02       Impact factor: 38.330

Review 6.  A genetic linkage map of the mouse: current applications and future prospects.

Authors:  N G Copeland; N A Jenkins; D J Gilbert; J T Eppig; L J Maltais; J C Miller; W F Dietrich; A Weaver; S E Lincoln; R G Steen
Journal:  Science       Date:  1993-10-01       Impact factor: 47.728

7.  Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis.

Authors:  W Xu; L M Mulligan; M A Ponder; L Liu; B A Smith; C G Mathew; B A Ponder
Journal:  Genes Chromosomes Cancer       Date:  1992-06       Impact factor: 5.006

8.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

Authors:  T Jacks; T S Shih; E M Schmitt; R T Bronson; A Bernards; R A Weinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

9.  Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity.

Authors:  M Tanaka; K Omura; Y Watanabe; Y Oda; I Nakanishi
Journal:  J Surg Oncol       Date:  1994-09       Impact factor: 3.454

Review 10.  Antioncogenes and human cancer.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more
  138 in total

1.  Bipartite interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans.

Authors:  Y P Hsueh; A M Roberts; M Volta; M Sheng; R G Roberts
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

Review 2.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

3.  Nf1 has an essential role in endothelial cells.

Authors:  Aaron D Gitler; Yuan Zhu; Fraz A Ismat; Min Min Lu; Yasutaka Yamauchi; Luis F Parada; Jonathan A Epstein
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

4.  Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Authors:  Vincent Chau; S Kyun Lim; Wei Mo; Chiachi Liu; Amish J Patel; Renée M McKay; Shuguang Wei; Bruce A Posner; Jef K De Brabander; Noelle S Williams; Luis F Parada; Lu Q Le
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

Review 5.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

6.  Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Authors:  Syed J Kazmi; Stephanie J Byer; Jenell M Eckert; Amy N Turk; Richard P H Huijbregts; Nicole M Brossier; William E Grizzle; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Am J Pathol       Date:  2013-01-13       Impact factor: 4.307

7.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1.

Authors:  K S G Cunha; E P Barboza; E C Da Fonseca
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

9.  Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk.

Authors:  Karlyne M Reilly
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

10.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.